On March 26, leading innovative drug company ASCENTAGE PHARMA GROUP released its full-year 2025 results. During the reporting period, the company achieved total revenue of 574 million Chinese yuan, demonstrating robust growth in commercialization. As the company's first commercial product, Olverembatinib experienced its first full sales year following inclusion in the national reimbursement drug list in 2025, achieving significant sales growth. Revenue for the product reached 435 million Chinese yuan, representing a substantial 81% increase year-over-year. The company's second product, Lisaftoclax, China's first domestically developed and marketed original Bcl-2 inhibitor, saw rapid sales expansion following its approval in July 2025, generating 70.58 million Chinese yuan in revenue within the five months to the end of the reporting period. The company's cash flow continued to improve, with ample monetary funds totaling approximately 2.47 billion Chinese yuan by the end of the reporting period. This performance growth is being efficiently driven by the "dual engines" of the two core products already on the market.

At the global clinical development level, the company also achieved milestone breakthroughs. The global registrational Phase III study for Olverembatinib as a first-line treatment for Ph+ ALL (POLARIS-1) and the global registrational Phase III study for Lisaftoclax in treating intermediate- to high-risk MDS (GLORA-4) both received permissions from the U.S. FDA and the European EMA in 2025. The company currently has multiple ongoing global registrational Phase III clinical studies, four of which have received permissions from the U.S. FDA and the European EMA.

To support the rapid business development, ASCENTAGE PHARMA GROUP's commercial team expanded quickly, surpassing 270 members by the end of 2025, covering over 1,500 hospitals nationwide, with plans for further expansion in 2026. In January 2025, the company successfully listed on NASDAQ, becoming the first biopharmaceutical company to achieve dual primary listings, following its initial listing in Hong Kong.

Dr. Dajun Yang, Chairman and CEO of ASCENTAGE PHARMA GROUP, stated, "2025 was a pivotal year for accelerating ASCENTAGE's global strategy. We achieved leapfrog breakthroughs across multiple dimensions, including product commercialization, global clinical development, pipeline innovation, and capital markets. Our commercialization strategy is steadily advancing, having successfully established a 'dual-engine' driving framework centered on Olverembatinib and Lisaftoclax. In 2026, we will continue to focus on unmet patient needs, accelerate the global clinical development of our core products, and strive to become a global leader in innovative hematological oncology."